You direct. The engine verifies.
Define the domain. Provide the corpus. The engine checks citation support, maps contradictions, and pressures the draft before it reaches a reviewer.
Sources: PubMed, Semantic Scholar, or your own corpus. Evidence verified before delivery. Weak claims rejected early.
Fabricated references are not hypothetical. An analysis reported by Retraction Watch in May 2026 found them in about 1 in 277 PubMed-indexed papers from early 2026.
How it works
A domain critic attacks mechanism plausibility, evidence strength, safety profile, novelty, and testability. Weak candidates are rejected before delivery.
1,538 papers. 21 candidate hypotheses. 1 survived verification.
A research team ran the complete psychedelic and ketamine antidepressant literature. The verification layer rejected most candidates. One survived with verified support.
the discovery: temporal stacking of mGlu2/3 antagonism after ketamine
Cross-referenced papers rarely read together. The real value: unsupported ideas do not masquerade as conclusions.
All 7 directions, 21 hypotheses
| Direction | Hypotheses | Best Verdict | Key Finding |
|---|---|---|---|
| mGlu2/3 + Ketamine Stacking | 3 | VIABLE | Temporal stacking extends neuroplasticity window |
| 5-HT2A Receptor Modulation | 3 | WEAK | Partial agonist approach needs more specificity data |
| Muscimol + SSRI Interactions | 3 | WEAK | Safety finding: serotonin syndrome risk flagged |
| Neuroplasticity Cascades | 3 | WEAK | BDNF timing windows need dose-response data |
| Default Mode Network | 3 | REJECTED | Mechanism too diffuse for actionable protocol |
| Gut-Brain Axis | 3 | REJECTED | Insufficient mechanistic evidence for psychedelic link |
| Epigenetic Markers | 3 | REJECTED | Too speculative for current evidence base |
It finds risks too.
case study bonus: drug interaction safety signal
The engine flagged a triple interaction: muscimol + trazodone + sertraline creating serotonergic excess. Emerged from combinatorial analysis across 1,538 papers — too diffuse for manual review.
Any domain. The engine catches contradictions and safety signals that fast synthesis flattens away.
Adversarial critique from independent model families surfaces failure modes a single-model review can miss.
Slower than a single-pass review. Requires a well-formed question.
Verification by research domain.
Domain-specific corpora. Segment-tuned proof points. Same adversarial pipeline.
Psychedelics research
Ketamine, psilocybin, MDMA. 1,538-paper corpus.
oncologyImmunotherapy research
Checkpoint inhibitors, biomarkers. 8,269-paper corpus.
ai safetyAlignment research
Cross-architecture adversarial review. 744-paper corpus.
clinical aiDiagnostic AI research
SaMD validation, clinical decision support. 656-paper corpus.
cardiologyCardiovascular research
GLP-1, SGLT2, cardiovascular outcomes. Adversarial review.
neurologyAlzheimer's research
Biomarkers, neurodegeneration, trial design. Citations verified. Contradictions surfaced.
institutionalR&D institutions
Cross-model verification for R&D institutions.
Run one claim through the pipeline.
Send the corpus and question. We confirm the review scope before work starts.
[ submit claim ]